中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 8
Aug.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(8): 1943-1947

Research advances in alcoholic liver disease with sarcopenia

DOI: 10.3969/j.issn.1001-5256.2021.08.043
  • 1.

    Department of Pharmacy, 960 Hospital of PLA Joint Logistics Support Force, Jinan 250031, China

  • 2.

    Liver Disease Center, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China

  • 3.

    Liver Disease Center, Beijing Ditan Teaching Hospital, Peking University Health Science Center, Beijing 100015, China

  • 4.

    Second Department of Hepatology, The Forth People's Hospital of Qinghai Province, Xining 810000, China

Research funding:

National Science and Technology Major Project (2017ZX10202202);

National Science and Technology Major Project (2018ZX10715-005);

Qinghai Provincial High-end and Innovative 1000 Talents Plan (2019-24);

Chinese Foundation for Hepatitis Prevention and Control-TianQing Liver Disease Research Fund (TQGB20210050)

  • Received Date: 2021-01-21
  • Accepted Date: 2021-02-05
  • Published Date: 2021-08-20
    Abstract
  • Alcoholic liver disease (ALD) is one of the most common liver diseases affecting the health of the Chinese people, and about 60% of ALD patients suffer from sarcopenia. Anorexia, inadequate intake of nutrients, disorder of digestion and absorption, reduction in physical activity, and increase in blood ammonia are common causes of sarcopenia in patients with ALD; besides, alcohol and its metabolites may affect the synthesis of skeletal muscle protein and promote the autophagy of skeletal muscle cells through multiple signaling pathways. Patients with ALD and sarcopenia tend to have increased risks of poor prognosis, such as hepatic encephalopathy and liver cancer. Further studies are needed to investigate the interventions for patients with ALD and sarcopenia.

     

    • FullText(HTML)
  • loading
    • References(55)
  • [1]
    National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for alcoholic liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34(5): 939-946. DOI: 10.3760/cma.j.issn.1007-3418.2018.03.007.

    中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 酒精性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5): 939-946. DOI: 10.3760/cma.j.issn.1007-3418.2018.03.007.
    [2]
    CRUZ-JENTOFT AJ, BAHAT G, BAUER J, et al. Sarcopenia: Revised European consensus on definition and diagnosis[J]. Age Ageing, 2019, 48(4): 601. DOI: 10.1093/ageing/afz046.
    [3]
    CHEN LK, WOO J, ASSANTACHAI P, et al. Asian Working Group for Sarcopenia: 2019 Consensus update on sarcopenia diagnosis and treatment[J]. J Am Med Dir Assoc, 2020, 21(3): 300-307. e2. DOI: 10.1016/j.jamda.2019.12.012.
    [4]
    TRAUB J, BERGHEIM I, EIBISBERGER M, et al. Sarcopenia and liver cirrhosis-comparison of the European Working Group on sarcopenia criteria 2010 and 2019[J]. Nutrients, 2020, 12(2): 547. DOI: 10.3390/nu12020547.
    [5]
    HSU CS, KAO JH. Sarcopenia and chronic liver diseases[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(12): 1229-1244. DOI: 10.1080/17474124.2018.1534586.
    [6]
    European Association for the Study of the Liver. EASL clinical practice guidelines on nutrition in chronic liver disease[J]. J Hepatol, 2019, 70(1): 172-193. DOI: 10.1016/j.jhep.2018.06.024.
    [7]
    ITOH S, SHIRABE K, YOSHIZUMI T, et al. Skeletal muscle mass assessed by computed tomography correlates to muscle strength and physical performance at a liver-related hospital experience[J]. Hepatol Res, 2016, 46(4): 292-297. DOI: 10.1111/hepr.12537.
    [8]
    SCHWEITZER L, GEISLER C, POURHASSAN M, et al. What is the best reference site for a single MRI slice to assess whole-body skeletal muscle and adipose tissue volumes in healthy adults?[J]. Am J Clin Nutr, 2015, 102(1): 58-65. DOI: 10.3945/ajcn.115.111203.
    [9]
    TAGUCHI S, AKAMATSU N, NAKAGAWA T, et al. Sarcopenia evaluated using the skeletal muscle index is a significant prognostic factor for metastatic urothelial carcinoma[J]. Clin Genitourin Cancer, 2016, 14(3): 237-243. DOI: 10.1016/j.clgc.2015.07.015.
    [10]
    SCHWEITZER L, GEISLER C, POURHASSAN M, et al. Estimation of skeletal muscle mass and visceral adipose tissue volume by a single magnetic resonance imaging slice in healthy elderly adults[J]. J Nutr, 2016, 146(10): 2143-2148. DOI: 10.3945/jn.116.236844.
    [11]
    PRADO CM, LIEFFERS JR, MCCARGAR LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study[J]. Lancet Oncol, 2008, 9(7): 629-635. DOI: 10.1016/S1470-2045(08)70153-0.
    [12]
    CAREY EJ, LAI JC, WANG CW, et al. A multicenter study to define sarcopenia in patients with end-stage liver disease[J]. Liver Transpl, 2017, 23(5): 625-633. DOI: 10.1002/lt.24750.
    [13]
    ROMAGNA ES, APPEL-DA-SILVA MC, SUWA E, et al. Muscle depletion in cirrhotic patients assessed using computed tomography: A cross-sectional study[J]. Sao Paulo Med J, 2020, 138(2): 152-157. DOI: 10.1590/1516-3180.2019.0436.R1.19122019.
    [14]
    IMAI K, TAKAI K, WATANABE S, et al. Sarcopenia impairs prognosis of patients with hepatocellular carcinoma: The role of liver functional reserve and tumor-related factors in loss of skeletal muscle volume[J]. Nutrients, 2017, 9(10): 1054. DOI: 10.3390/nu9101054.
    [15]
    SHI ZW. Association of L3 skeletal muscle index and prognosis in patients with liver cirrhosis[D]. Shanghai: The Naval Medical University of the People's Liberation Army, 2019.

    石志文. L3骨骼肌指数评估肝硬化患者预后的相关研究[D]. 上海: 中国人民解放军海军军医大学, 2019.
    [16]
    GU DH, KIM MY, SEO YS, et al. Clinical usefulness of psoas muscle thickness for the diagnosis of sarcopenia in patients with liver cirrhosis[J]. Clin Mol Hepatol, 2018, 24(3): 319-330. DOI: 10.3350/cmh.2017.0077.
    [17]
    KIM G, KANG SH, KIM MY, et al. Prognostic value of sarcopenia in patients with liver cirrhosis: A systematic review and meta-analysis[J]. PLoS One, 2017, 12(10): e0186990. DOI: 10.1371/journal.pone.0186990.
    [18]
    DASARATHY S. Nutrition and alcoholic liver disease: Effects of alcoholism on nutrition, effects of nutrition on alcoholic liver disease, and nutritional therapies for alcoholic liver disease[J]. Clin Liver Dis, 2016, 20(3): 535-550. DOI: 10.1016/j.cld.2016.02.010.
    [19]
    DASARATHY J, MCCULLOUGH AJ, DASARATHY S. Sarcopenia in alcoholic liver disease: Clinical and molecular advances[J]. Alcohol Clin Exp Res, 2017, 41(8): 1419-1431. DOI: 10.1111/acer.13425.
    [20]
    STEINER JL, LANG CH. Dysregulation of skeletal muscle protein metabolism by alcohol[J]. Am J Physiol Endocrinol Metab, 2015, 308(9): e699-e712. DOI: 10.1152/ajpendo.00006.2015.
    [21]
    WELCH N, DASARATHY J, RUNKANA A, et al. Continued muscle loss increases mortality in cirrhosis: Impact of aetiology of liver disease[J]. Liver Int, 2020, 40(5): 1178-1188. DOI: 10.1111/liv.14358.
    [22]
    DASARATHY S, MERLI M. Sarcopenia from mechanism to diagnosis and treatment in liver disease[J]. J Hepatol, 2016, 65(6): 1232-1244. DOI: 10.1016/j.jhep.2016.07.040.
    [23]
    DAVULURI G, WELCH N, SEKAR J, et al. Activated protein phosphatase 2A disrupts nutrient sensing balance between mTORC1 and AMPK causing sarcopenia in alcoholic liver disease[J]. Hepatology, 2021, 73(5): 1892-1908. DOI: 10.1002/hep.31524.
    [24]
    KANT S, DAVULURI G, ALCHIRAZI KA, et al. Ethanol sensitizes skeletal muscle to ammonia-induced molecular perturbations[J]. J Biol Chem, 2019, 294(18): 7231-7244. DOI: 10.1074/jbc.RA118.005411.
    [25]
    KUMAR A, DAVULURI G, WELCH N, et al. Oxidative stress mediates ethanol-induced skeletal muscle mitochondrial dysfunction and dysregulated protein synthesis and autophagy[J]. Free Radic Biol Med, 2019, 145: 284-299. DOI: 10.1016/j.freeradbiomed.2019.09.031.
    [26]
    ADLER K, MOLINA PE, SIMON L. Epigenomic mechanisms of alcohol-induced impaired differentiation of skeletal muscle stem cells; role of Class ⅡA histone deacetylases[J]. Physiol Genomics, 2019, 51(9): 471-479. DOI: 10.1152/physiolgenomics.00043.2019.
    [27]
    HANAI T, SHIRAKI M, NISHIMURA K, et al. Sarcopenia impairs prognosis of patients with liver cirrhosis[J]. Nutrition, 2015, 31(1): 193-199. DOI: 10.1016/j.nut.2014.07.005.
    [28]
    XIAO HJ, YE Q, ZHANG M, et al. Risk factors of cirrhosis combined with sarcopenia and their impact on clinical outcomes[J]. Chin J Hepatol, 2020, 28(1): 53-57. DOI: 10.3760/cma.j.issn.1007-3418.2020.01.013.

    肖慧娟, 叶青, 张明, 等. 肝硬化合并肌肉减少症的危险因素及其对临床结局的影响[J]. 中华肝脏病杂志, 2020, 28(1): 53-57. DOI: 10.3760/cma.j.issn.1007-3418.2020.01.013.
    [29]
    MONTANO-LOZA AJ, MEZA-JUNCO J, PRADO CM, et al. Muscle wasting is associated with mortality in patients with cirrhosis[J]. Clin Gastroenterol Hepatol, 2012, 10(2): 166-173. DOI: 10.1016/j.cgh.2011.08.028.
    [30]
    WIJARNPREECHA K, WERLANG M, PANJAWATANAN P, et al. Association between sarcopenia and hepatic encephalopathy: A systematic review and meta-analysis[J]. Ann Hepatol, 2020, 19(3): 245-250. DOI: 10.1016/j.aohep.2019.06.007.
    [31]
    BHANJI RA, MOCTEZUMA-VELAZQUEZ C, DUARTE-ROJO A, et al. Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis[J]. Hepatol Int, 2018, 12(4): 377-386. DOI: 10.1007/s12072-018-9875-9.
    [32]
    CHANG KV, CHEN JD, WU WT, et al. Is sarcopenia associated with hepatic encephalopathy in liver cirrhosis? A systematic review and meta-analysis[J]. J Formos Med Assoc, 2019, 118(4): 833-842. DOI: 10.1016/j.jfma.2018.09.011.
    [33]
    FOZOUNI L, WANG CW, LAI JC. Sex differences in the association between frailty and sarcopenia in patients with cirrhosis[J]. Clin Transl Gastroenterol, 2019, 10(12): e00102. DOI: 10.14309/ctg.0000000000000102.
    [34]
    NARDELLI S, LATTANZI B, TORRISI S, et al. Sarcopenia is risk factor for development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement[J]. Clin Gastroenterol Hepatol, 2017, 15(6): 934-936. DOI: 10.1016/j.cgh.2016.10.028.
    [35]
    FENG Z, ZHAO H, JIANG Y, et al. Sarcopenia associates with increased risk of hepatocellular carcinoma among male patients with cirrhosis[J]. Clin Nutr, 2020, 39(10): 3132-3139. DOI: 10.1016/j.clnu.2020.01.021.
    [36]
    KUO SZ, AHMAD M, DUNN MA, et al. Sarcopenia predicts post-transplant mortality in acutely ill men undergoing urgent evaluation and liver transplantation[J]. Transplantation, 2019, 103(11): 2312-2317. DOI: 10.1097/TP.0000000000002741.
    [37]
    FUJIWARA N, NAKAGAWA H, KUDO Y, et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma[J]. J Hepatol, 2015, 63(1): 131-140. DOI: 10.1016/j.jhep.2015.02.031.
    [38]
    SALMAN MA, OMAR H, MIKHAIL H, et al. Sarcopenia increases 1-year mortality after surgical resection of hepatocellular carcinoma[J]. ANZ J Surg, 2020, 90(5): 781-785. DOI: 10.1111/ans.15647.
    [39]
    TANDON P, NEY M, IRWIN I, et al. Severe muscle depletion in patients on the liver transplant wait list: Its prevalence and independent prognostic value[J]. Liver Transpl, 2012, 18(10): 1209-1216. DOI: 10.1002/lt.23495.
    [40]
    AL-AZZAWI Y, ALBO B, FASULLO M, et al. Sarcopenia is associated with longer hospital stay and multiorgan dysfunction in alcoholic hepatitis[J]. Eur J Gastroenterol Hepatol, 2020, 32(6): 733-738. DOI: 10.1097/MEG.0000000000001583.
    [41]
    FIALLA AD, ISRAELSEN M, HAMBERG O, et al. Nutritional therapy in cirrhosis or alcoholic hepatitis: A systematic review and meta-analysis[J]. Liver Int, 2015, 35(9): 2072-2078. DOI: 10.1111/liv.12798.
    [42]
    PURI P, THURSZ M. Intensive enteral nutrition in alcoholic hepatitis: More food for thought[J]. Gastroenterology, 2016, 150(4): 803-805. DOI: 10.1053/j.gastro.2016.02.061.
    [43]
    TSIEN CD, MCCULLOUGH AJ, DASARATHY S. Late evening snack: Exploiting a period of anabolic opportunity in cirrhosis[J]. J Gastroenterol Hepatol, 2012, 27(3): 430-441. DOI: 10.1111/j.1440-1746.2011.06951.x.
    [44]
    ANAND AC. Nutrition and muscle in cirrhosis[J]. J Clin Exp Hepatol, 2017, 7(4): 340-357. DOI: 10.1016/j.jceh.2017.11.001.
    [45]
    DAVULURI G, KROKOWSKI D, GUAN BJ, et al. Metabolic adaptation of skeletal muscle to hyperammonemia drives the beneficial effects of l-leucine in cirrhosis[J]. J Hepatol, 2016, 65(5): 929-937. DOI: 10.1016/j.jhep.2016.06.004.
    [46]
    TSIEN C, DAVULURI G, SINGH D, et al. Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis[J]. Hepatology, 2015, 61(6): 2018-2029. DOI: 10.1002/hep.27717.
    [47]
    LI JH, YAO J, YUAN LL. Association between sarcopenia and hepatic encephalopathy and advances in diagnosis and treatment[J]. J Clin Hepatol, 2020, 36(6): 1412-1414. DOI: 10.3969/j.issn.1001-5256.2020.06.049.

    李建宏, 姚佳, 原丽莉. 肌肉减少症与肝性脑病的关系及诊疗进展[J]. 临床肝胆病杂志, 2020, 36(6): 1412-1414. DOI: 10.3969/j.issn.1001-5256.2020.06.049.
    [48]
    DIDSBURY M, MCGEE RG, TONG A, et al. Exercise training in solid organ transplant recipients: A systematic review and meta-analysis[J]. Transplantation, 2013, 95(5): 679-687. DOI: 10.1097/TP.0b013e31827a3d3e.
    [49]
    NASEER M, TURSE EP, SYED A, et al. Interventions to improve sarcopenia in cirrhosis: A systematic review[J]. World J Clin Cases, 2019, 7(2): 156-170. DOI: 10.12998/wjcc.v7.i2.156.
    [50]
    HIRAOKA A, MICHITAKA K, KIGUCHI D, et al. Efficacy of branched-chain amino acid supplementation and walking exercise for preventing sarcopenia in patients with liver cirrhosis[J]. Eur J Gastroenterol Hepatol, 2017, 29(12): 1416-1423. DOI: 10.1097/MEG.0000000000000986.
    [51]
    ROMÁN E, TORRADES MT, NADAL MJ, et al. Randomized pilot study: Effects of an exercise programme and leucine supplementation in patients with cirrhosis[J]. Dig Dis Sci, 2014, 59(8): 1966-1975. DOI: 10.1007/s10620-014-3086-6.
    [52]
    WANG BY. Importance of the clinical research on alcoholic hepatitis[J]. J Clin Hepatol, 2019, 35(3): 469-471. DOI: 10.3969/j.issn.1001-5256.2019.03.002.

    王炳元. 重视酒精性肝炎的临床研究[J]. 临床肝胆病杂志, 2019, 35(3): 469-471. DOI: 10.3969/j.issn.1001-5256.2019.03.002.
    [53]
    SINCLAIR M, GROSSMANN M, HOERMANN R, et al. Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial[J]. J Hepatol, 2016, 65(5): 906-913. DOI: 10.1016/j.jhep.2016.06.007.
    [54]
    KUMAR A, DAVULURI G, SILVA R, et al. Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis[J]. Hepatology, 2017, 65(6): 2045-2058. DOI: 10.1002/hep.29107.
    [55]
    KWAK JY, KWON KS. Pharmacological interventions for treatment of sarcopenia: Current status of drug development for sarcopenia[J]. Ann Geriatr Med Res, 2019, 23(3): 98-104. DOI: 10.4235/agmr.19.0028.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (555) PDF downloads(59) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return